Xarelto Plaintiffs From Texas File Lawsuit Claiming Drug’s Manufacturers Failed To Warn Consumers Of Concerning Side Effects

March 31, 2016 – – BloodThinnerHelp.com reports on concerning details from a lawsuit filed against Xarelto manufacturers Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceuticals. Xarelto is a new-generation blood-thinning drug which first appeared on the market in 2011, providing blood thinner patients with new freedoms that traditional blood thinners had been unable to.

This particular lawsuit was first filed in the Eastern District of New York under case number 1:14-cv-04524 by a couple from Texas. The couple claims that defendants Janssen and Bayer failed to properly inform consumers and patients about potentially dangerous risks linked to the use of Xarelto.

Detailing how they came to this conclusion, the plaintiffs explain that the wife was prescribed Xarelto by a family physician as a treatment for her atrial fibrillation heart condition, which can potentially put sufferers at increased risk for strokes. The woman claims that she used Xarelto for just 5 month’s time before she suddenly experienced a potentially life-threatening internal bleed. The bleed, she says, has left her with the need for long-term medical care, and, therefore, continued mounting medical bills.

Xarelto gained approval by the United States Food and Drug Administration in 2011. It was intended as a treatment for patients recovering from knee or hip replacement surgeries, who were deemed at increased risk for the development of blood clots or strokes. Although it gained FDA market approval, Xarelto was also the recipient of two “black box” warnings from the agency. These “black box” warnings are the most strict warnings the FDA is able to attach to a product before fully pulling it from the market.

Unfortunately, these Texas plaintiffs are not alone in their claims. Across the United States, thousands of plaintiffs have now filed lawsuits against Xarelto manufacturers alleging much the same. Many plaintiffs discuss a variety of bleeding episodes, some of which were fatal, and all of which, they claim, were caused by the anticoagulant.

Cases federally-filed against Xarelto have now been transferred and consolidated to a single court by the U.S. Judicial Panel on Multidistrict Litigation. These cases number over 2,800 today and are being overseen in the Eastern District of Louisiana by Judge Eldon Fallon. They were consolidated to form MDL number 2592. In addition, more than 600 other Xarelto-related lawsuits have been consolidated in Philadelphia, Pennsylvania by the Court of Common Pleas, forming a mass tort program.

As thousands of Xarelto plaintiffs await trial, Attorney Joseph Osborne is working to help other patients who feel that they have been negatively affected by using the drug. He wants to ensure that these individuals are provided the opportunity of fully investigating their legal rights in the matter. Affected individuals may be entitled to legal action and significant compensation. To help assist, Attorney Osborne is currently offering free legal consultations to qualified parties.

To request additional information on Xarelto lawsuits, or to ask questions, contact Attorney Joseph Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009006